Close menu




March 24th, 2022 | 13:07 CET

BioNTech, Cardiol Therapeutics, Moderna - New target groups to boost business

  • Biotechnology
Photo credits: pixabay.com

Infection figures remain at record levels. Health authorities reported 283,732 new infections to the Robert Koch Institute, 21,139 cases more than a week ago. In contrast, the pace of vaccination is limping, with the vaccination status of the overall population changing only marginally and remaining at 75.8% basic immunization. Chancellor Scholz is now calling for compulsory vaccination to counter the threat of another wave of Corona in the fall. This message is likely to be grist to the mill for the vaccine manufacturers, whose ratings, similar to the vaccination rates, have dropped sharply in recent weeks.

time to read: 2 minutes | Author: Stefan Feulner
ISIN:

Table of contents:


    Moderna for the little ones

    The vaccine manufacturers' target group is being expanded once again. Moderna is currently testing its vaccine on children aged six months to five years. Initial results have been positive for the manufacturer. Administering the preparation twice produces robust antibody levels and is well tolerated, Moderna announced on Wednesday. According to the data, the vaccine protects rather poorly against infections with the Omicron variant, similar to adults, but there have been no severe disease developments. The Company now plans to submit regulatory applications for this age group to the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other competent authorities "as soon as possible."

    The interim results are based on data from a total of 6,700 children, with 4,200 between 2 and 6 years old and 2,500 children between six months and two years old. Adverse effects were reported to be mild or moderate and more common after the second dose, such as fever above 38 degrees. There were no deaths or inflammation of the heart muscle or sac or any severe inflammatory reactions.

    Expensive vaccine manufacturer

    Moderna shares rallied somewhat after a sharp correction from USD 497.29 to USD 124 and are trading at USD 180, with a broad resistance front standing in the way of a further run-up. Fundamentally, the share is still valued at a sporting USD 77.64 billion.

    Despite its strong annual results, the Mainz-based vaccine producer BioNTech is also struggling with its current valuations and possible higher price targets. The stock market value of the German flagship company is USD 42.35 billion. In our opinion, an investment, even at the current, corrected level, does not impose itself.

    Heart muscle inflammation as a result of mRNA vaccination

    According to scientists, heart muscle or pericardial inflammation due to mRNA vaccination is rare, but it still occurs from time to time. The first cases were reported in the spring of 2021. Studies in the US also linked Corona vaccination to myocarditis or pericarditis.

    The treatment of myocarditis belongs to the future therapies of Cardiol Therapeutics. In light of the fact that myocarditis is also one of the side effects of current vaccination campaigns, the scientific community is likely to be eagerly awaiting the completion of clinical trials. In addition, the Oakville, Canada-based company's lead product, CardiolRx, is based on an oral cannabidiol formulation that is pharmaceutically manufactured according to cGMP and is currently being evaluated in a Phase II/III clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19. CEO David Elsley expects this trial to be completed during the second half of 2022.

    The heart failure market is worth approximately USD 20 billion annually, and more than 26 million people in the Western world receive long-term treatment for this disease. Cardiol Therapeutics is funded for at least the next 24 months with a USD 50 million capital increase that took place in the fourth quarter of last year. At the same time, the Company is valued at a market capitalization of just EUR 86.81 million. Should the study data deliver positive results in the second half of 2022, Cardiol should grow wings. The share price currently stands at CAD 1.81 or EUR 1.31. The analysts at GBC Research already see a ten-bagger in the stock and assigned a price target of CAD 17.49 in their latest study.


    Despite new records in the infection figures, the willingness to vaccinate is declining, and not only in Germany. The already ambitiously valued vaccine manufacturers Moderna and BioNTech are no bargains even at current levels. In contrast, analysts see no less than a tenfold increase for Cardiol Therapeutics.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.

    Read

    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?

    Read

    Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST

    Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!

    • Biotechnology
    • Pharma
    • vaccine

    Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.

    Read